Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Expensify Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.81B), while Expensify Inc trades at $2.44 (market cap $223.41M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 12.6× Expensify Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Expensify Inc for 41 Days on average.
| DYN | EXFY | |
|---|---|---|
Market Cap | $2.81B | $223.41M |
Volume | 2,195,902 | 450,483 |
Sector | Health | Technology |
52-Week High | $26.78 | $2.72 |
52-Week Low | $14.60 | $0.75 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $2.13B | $163.03M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Expensify (EXFY) trades at $2.45, showing modest daily gains of 0.41%. The stock exhibits a bullish technical signal with strong moving average support. Fundamentally, the company maintains solid revenue around $142M but faces profitability challenges with negative net margins. Recent quarterly earnings show mixed results with two beats and one miss. Analyst sentiment leans positive with a 50% buy rating and $13.75 consensus price target, representing significant upside potential from current levels.
EXFY presents a high-risk, high-reward opportunity with substantial analyst upside but persistent profitability concerns. The company's expansion into European markets and AI integrations provide growth catalysts, though negative earnings and cash flow volatility remain key risks. Investors should weigh the significant price target premium against the company's ongoing transition to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
